MARKET

CTLT

CTLT

Catalent
NYSE

Real-time Quotes | Nasdaq Last Sale

113.71
+1.46
+1.30%
After Hours: 113.54 -0.17 -0.15% 16:37 02/26 EST
OPEN
112.94
PREV CLOSE
112.25
HIGH
114.55
LOW
111.48
VOLUME
983.56K
TURNOVER
--
52 WEEK HIGH
127.68
52 WEEK LOW
31.04
MARKET CAP
19.36B
P/E (TTM)
63.96
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
JNJ to deliver fewer COVID-19 vaccine doses amid production problems: FT
Due to production problems suffered by Catalent (NYSE:CTLT), the manufacturing partner of Johnson & Johnson (JNJ), the U.S. government could receive fewer COVID-19 vaccine deliveries from the company, according to Financial Times.Today,
Seekingalpha · 1d ago
Indian Schizophrenia Drugs Market Size, Share, Growth, Research and Forecast 2020-2026
Feb 26, 2021 (Market Insight Reports) -- Indian schizophrenia drugs market is projected to grow at a significant CAGR of 4.0% during the forecast period...
Market Insight Reports · 2d ago
Moderna CEO details the company's momentous vaccine production
Moderna CEO reveals behind-the-scenes of ramping up manufacturing as the company grew from a clinical-stage company to a commercial company.
Yahoo Finance · 3d ago
Healthcare Contract Development And Manufacturing Organization Market Report 2020, Trends and Forecast To 2027
Japan, Japan, Thu, 25 Feb 2021 05:14:40 / Comserve Inc. / -- Competitive Analysis: Catalent Inc., Lonza Group Ltd., Recipharm AB, Siegfried Holding AG,...
Comserve · 3d ago
Moderna expands vaccine production, sets 2022 target of 1.4B doses
Moderna announces new expansion plans, and a study for its booster shot that targets the South African variant.
Yahoo Finance · 4d ago
Pharmaceutical Packaging Market to Witness Astonishing Growth with Amcor, Catalent, Nipro
Feb 24, 2021 (Market Insight Reports) -- HTF MI recently added Global Pharmaceutical Packaging Market Study that gives deep analysis of current scenario of...
Market Insight Reports · 4d ago
Intra-Cellular expands pipeline with a new therapy targeting dementia
Intra-Cellular Therapies ([[ITCI]] +2.1%) has announced a pipeline expansion with the addition of ITI-1284 ODT-SL, a deuterated form of lumateperone.Lumateperone is a new molecular compound formulated as an orally disintegrating tablet for
Seekingalpha · 4d ago
Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
Benzinga · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTLT. Analyze the recent business situations of Catalent through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTLT stock price target is 133.90 with a high estimate of 142.00 and a low estimate of 120.00.
EPS
Institutional Holdings
Institutions: 671
Institutional Holdings: 183.13M
% Owned: 107.58%
Shares Outstanding: 170.23M
TypeInstitutionsShares
Increased
196
5.93M
New
127
8.16M
Decreased
165
9.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.05%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/Director
John Chiminski
President/Chief Operating Officer
Alessandro Maselli
Chief Financial Officer/Senior Vice President
Wetteny Joseph
Corporate Executive
Jonathan Arnold
Corporate Executive
Karen Flynn
Corporate Executive
Manja Boerman
Corporate Executive
Aristippos Gennadios
Corporate Executive
Ricci Whitlow
Chief Human Resource Officer/Senior Vice President
Ricardo Pravda
Corporate Executive
Mario Gargiulo
Senior Vice President/Chief Information Officer
Charles Lickfold
Senior Vice President/General Counsel/Secretary
Steven Fasman
Senior Vice President
Michael Grippo
Senior Vice President
Scott Gunther
Senior Vice President
Kay Schmidt
Senior Vice President
Mike Grippo
Vice President
Z Mahdavi
Lead Director/Independent Director
Jack Stahl
Independent Director
Madhavan Balachandran
Vice President - Operations
Jim Walter
Independent Director
J. Martin Carroll
Independent Director
Rolf Classon
Independent Director
Rosemary Crane
Independent Director
John Greisch
Independent Director
Christa Kreuzburg
Independent Director
Gregory Lucier
Independent Director
Donald Morel
Independent Director
Peter Zippelius
  • Dividends
  • Splits
  • Insider Activity
No Data
About CTLT
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Webull offers kinds of Catalent Inc stock information, including NYSE:CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.